维普期刊资源整合服务平台（V6.5）

31篇 您的检索式：作者名="Trail PA"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and inducestumor apoptosis and hypoxia in RCC xenograft models 显示文摘	CHANG YS ADNANE J TRAIL PA	2006	CancerChemother Pharmacol2006，59，5：	1
2	Sorafenib(BAY 43-9006)inhibits tumor growth and vascularization and induces tumorapoptosis and hypoxia in RCC xenograft models显示文摘	Chang YS Adnane J Trail PA	2007	Cancer Chemother Pharnmcol2007，59，56：	1
3	Monoclonal antibody drug immunoconjugates for targeted treatment of cancer 显示文摘	Trail PA King HD Dubowchik GM	2003	Cancer Immunol Immunother2003，52，5：	1
4	Sorafenib(BAY 43-9006,Nexavar),a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature显示文摘	Adnane L Trail PA Taylor I	2006	Methods Enzymol2006，407，：	1
5	Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models显示文摘	Chang YS Adnane J Trail PA	2007	Cancer Chemother Pharmacol2007，59，5：	1
6	Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models显示文摘	Chang YS Adnane J Trail PA	2007	Cancer Chemother Pharmacol2007，59，5：	1
7	Antibody drug conjugates as cancer therapeutics 显示文摘	Trail PA	2013	Antibodies2013，2，1：	1
8	Sorafenib inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograftmodels显示文摘	Chang YS Adnane J Trail PA	2007	Cancer Chemother Phamacol2007，59，5：	1
9	Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model 显示文摘	Bemsen LG Trail PA Hellstro I	2000	Neurosurgery2000，46，3：	1
10	Sorafenib (BAY 43-9006,Nexavar),a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature显示文摘	Adnane L Trail PA Taylor I		0，，：	1
11	Sorafenib (Bay43-9006) in-hibits tumor rowth and vascularization andinduces tumor apoptosis andhypoxia in RCC xenograft models显示文摘	Chang YS Adnane J Trail PA	2007	Cancer Chem Pharm2007，59，5：	1
12	Sorafenib(BAY43-9006)inh ibits tumor growth and vascularization and inducestumor a poptosis and hypoxia in RCC xenograft models显示文摘	CHANG YS ADNANE J TRAIL PA	2007	Cancer Ch emother Pharmacol2007，59，5：	1
13	Sorafenib(BAY 43-9006)inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograftmodels显示文摘	Chang YS Adnane J Trail PA	2007	Cancer Chemother Pharmacol2007，59，5：	1
14	Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models显示文摘	Chang YS Adnane J Trail PA	2007	Cancer Chemother Pharmacol2007，59，：	1
15	Sorafenib (BAY 43-9006,Nexavar),a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature显示文摘	Adnane L Trail PA Taylor I		0，，：	1
16	Sorafenib ( BAY43-9006 ) inhibits tumor growth and vascularization and induces tumor apoptosis and hypox- ia in RCC xenograft models 显示文摘	Chang YS Adnane J Trail PA	2007	Cancer Chemotherapy Pharmacol2007，59，5：	1
17	Sorafenib ( BAY 43-9006) inhibits tumor growth and vascularization and induces tumor ap- optosis and hypoxia in RCC xenograft models 显示文摘	Chang YS Adnane J Trail PA	2007	Cancer Che- mother Pharmacol2007，59，5：	1
18	Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models显示文摘	Chang YS Adnane J Trail PA	2007	Cancer Chemother Pharmacol2007，59，5：	1
19	Sorafenib(BAY43- 9006) inhibits tumor growth and vaseularization and induces tumor apoptosis and hypoxia in RCC xenograft models显示文摘	Chang YS Adnane J Trail PA	2007	Cancer Chemotherapy Pharmacol2007，59，56：	1
20	Monoclonal antibody drug conjugates in the treatment of cancer显示文摘	Trail PA Bianchi AB	1999	Curr Opin Immunol1999，11，：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示